Handelsavisen
prelaunch
Companies Healthcare TRA.HM
TR
TRA.HM Pharmaceuticals

Tra.Hm

$80 000,00
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
5,19 %
Op margin
12,8 %
ROE
16,1 %
Net margin
9,4 %
Debt / equity
0,09
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

TRA.HM operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.

Business. TRA.HM operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
16,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning TRA.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to TRA.HM. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    TRA.HM operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED

    TRA.HM maintains a strong liquidity position with a current ratio of 2.76, indicating the company can cover its short-term liabilities more than two times over. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints despite its high cash and equivalents balance of 61.97 billion VND. The debt-to-equity ratio of 0.09 suggests a conservative capital structure, with total liabilities at 769.79 billion VND and total equity at 1.55 trillion VND.

    In terms of profitability, TRA.HM generates a return on equity of 16.08% and a return on assets of 10.75%, both of which are strong indicators of efficient capital utilization and asset management. The company's operating income of 341.05 billion VND and net income of 249.65 billion VND reflect a healthy margin structure, although the gross profit of 1.42 trillion VND suggests a need to monitor cost of goods sold trends.

    The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification data provided in the available sources. This lack of segment and geographic detail limits the ability to assess exposure to regional or product-specific risks.

    TRA.HM's growth trajectory is supported by a revenue base of 2.66 trillion VND, with operating cash flow of 282.97 billion VND and free cash flow of 95.33 billion VND. While no specific growth projections are provided, the company's capital expenditure of -109.49 billion VND indicates a focus on cost management rather than expansion.

    The risk assessment highlights a medium liquidity risk due to the negative net cash position after debt, despite a low dilution risk. No dilution sources are explicitly cited in the available documents, and the company's capital structure remains stable with no near-term dilution pressure.

    No recent events, such as filings or transcripts, are available in the provided data to inform the company's strategic direction or operational developments.

    Key takeaways
    • TRA.HM maintains a conservative capital structure with a low debt-to-equity ratio of 0.09.
    • The company's return on equity of 16.08% and return on assets of 10.75% indicate strong profitability.
    • Despite a high current ratio of 2.76, the negative net cash position after debt raises liquidity concerns.
    • The company's revenue and segment data are not geographically or product-wise diversified, increasing concentration risk.
    • No dilution sources are identified, and the risk of near-term equity issuance is low.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $80 000,00
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $1.55T
    Net cash
    -$74.19B
    Current ratio
    2.8
    Debt / equity
    0.1
    ROA
    10.8%
    ROE
    16.1%
    Cash conversion
    113.0%
    CapEx / revenue
    -4.1%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin12,8 %Above median
    Net Margin9,4 %Above median
    ROE16,1 %Above P75
    Capex / Rev-4,1 %Above median
    D/E0,09Above median
    Cash Conv1,13Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • TRA.HM Market data — financials · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    TRA.HMCanonical
    — · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage